Uveitis

NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, Yolande Barnard, vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, discusses Xipere (triamcinolone acetonide injectable suspension).

Eye exam reminders at every visit are associated with higher uveitis knowledge among patients with juvenile idiopathic arthritis and their parents, according to data published in Pediatric Rheumatology.

A 39-year-old woman was referred to the uveitis clinic at the New England Eye Center for a few weeks’ history of bilateral pain, blurry vision, floaters and photophobia.

The FDA has approved Xipere for suprachoroidal use in the treatment of macular edema associated with uveitis, according to a press release from Bausch + Lomb and Clearside Biomedical.

Young ophthalmologists looking to specialize in retina and uveitis management can tailor their career to be as specific or as broad as they like, according to a speaker at the Real World Ophthalmology meeting.

In this video from the virtual Euretina congress, Quan Dong Nguyen, MD, MSc, speaks about ABY-035, a novel biologic compound that has been demonstrated to be a potent interleukin-17A inhibitor with unique pharmacological properties.

Secukinumab and etanercept are associated with an increased risk for anterior uveitis in patients with spondyloarthritis, compared with monoclonal TNF inhibitors, according to data published in the Annals of the Rheumatic Diseases.

A 56-year-old woman presented to the ophthalmology office at the Lahey Clinic with 1 week of left eye pain associated with burning, injection and a left-sided headache without any vision changes.

Uveitis has a “significant impact” on visual functioning and vision-related quality of life among children with juvenile idiopathic arthritis, according to data published in Arthritis Care & Research.

Posterior uveitis is the most common form of involvement in intraocular tuberculosis.